Humanities
Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Journal of Education, Health and Sport

Treatment of malignant melanoma - a review of the literature
  • Home
  • /
  • Treatment of malignant melanoma - a review of the literature
  1. Home /
  2. Archives /
  3. Vol. 11 No. 9 (2021) /
  4. Review Articles

Treatment of malignant melanoma - a review of the literature

Authors

  • Natalia Kluz Medical University of Lublin https://orcid.org/0000-0002-5801-5913
  • Jakub Klas Medical University of Lublin https://orcid.org/0000-0002-4795-1909

DOI:

https://doi.org/10.12775/JEHS.2021.11.09.008

Keywords

malignant melanoma, immunotherapy, photodynamic therapy

Abstract

Melanoma is caused by genetic mutations in melanocytes, pigment-producing cells found in the skin, eye, inner ear, and soft meninges. Sun exposure, atypical nevi, previous history of melanoma, and the presence of multiple (≥40) common nevi were found to be associated with an increased risk of melanoma detection (OR: 1. 3; 95% CI: 1. 1-1. 6). Its prevalence is highest among light-skinned populations and in regions of lower latitudes. Significance of family history of melanoma and presence of congenital nevi were excluded. For localized primary melanoma, the dominant prognostic factors for survival are lesion thickness, ulceration, and lymph node involvement Understanding the pathogenesis of melanoma has been crucial in developing new therapeutic approaches. The characterization of oncogenic signaling pathways and interactions has made it possible to identify new targets for clinically effective therapies, such as pathway inhibitors and antibodies to immune checkpoints or the use of phototherapy. In this article we describe the  main signaling pathways which are deregulated in melanoma. We also mention how it has become a viable and crucial strategy for melanoma therapy and then thoroughly review the safety, clinical efficacy and progress regarding PDT- promising alternative therapy and the immunotherapies of melanoma in especially advanced metastatic stage basing on published clinical data and registered clinical trials, most of which are in phase III. 


References

Domingues B, Lopes JM, Soares P, Pópulo H. Melanoma treatment in review. Immunotargets Ther. 2018 Jun 7;7:35-49. doi: 10.2147/ITT.S134842. PMID: 29922629; PMCID: PMC5995433.

Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007 Feb 22;445(7130):851-7. doi: 10.1038/nature05661. PMID: 17314971

Tolleson WH. Human melanocyte biology, toxicology, and pathology. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2005;23(2):105-61. doi: 10.1080/10590500500234970. PMID: 16291526.

Pópulo H, Soares P, Lopes JM. Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert Opin Ther Targets. 2012 Jul;16(7):689-705. doi: 10.1517/14728222.2012.691472. Epub 2012 May 24. PMID: 22620498.

Matthews NH, Li WQ, Qureshi AA, Weinstock MA, Cho E. Epidemiology of Melanoma. In: Ward WH, Farma JM, editors. Cutaneous Melanoma: Etiology and Therapy [Internet]. Brisbane (AU): Codon Publications; 2017 Dec 21. Chapter 1. PMID: 29461782.

Hübner J, Waldmann A, Eisemann N, Noftz M, Geller AC, Weinstock MA, Volkmer B, Greinert R, Breitbart EW, Katalinic A. Association between risk factors and detection of cutaneous melanoma in the setting of a population-based skin cancer screening. Eur J Cancer Prev. 2018 Nov;27(6):563-569. doi: 10.1097/CEJ.0000000000000392. PMID: 28692584.

Homsi J, Kashani-Sabet M, Messina JL, Daud A. Cutaneous melanoma: prognostic factors. Cancer Control. 2005 Oct;12(4):223-9. doi: 10.1177/107327480501200403. PMID: 16258493.

von Schuckmann LA, Hughes MCB, Ghiasvand R, Malt M, van der Pols JC, Beesley VL, Khosrotehrani K, Smithers BM, Green AC. Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor. JAMA Dermatol. 2019 Jun 1;155(6):688-693. doi: 10.1001/jamadermatol.2019.0440. PMID: 31042258; PMCID: PMC6495363.

Etzkorn JR, Sharkey JM, Grunyk JW, Shin TM, Sobanko JF, Miller CJ. Frequency of and risk factors for tumor upstaging after wide local excision of primary cutaneous melanoma. J Am Acad Dermatol. 2017 Aug;77(2):341-348. doi: 10.1016/j.jaad.2017.03.018. PMID: 28601390.

Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S. Melanoma. Lancet. 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9. Erratum in: Lancet. 2019 Feb 23;393(10173):746. PMID: 30238891.

Cristiani CM, Garofalo C, Passacatini LC, Carbone E. New avenues for melanoma immunotherapy: Natural Killer cells? Scand J Immunol. 2020 Apr;91(4):e12861. doi: 10.1111/sji.12861. Epub 2020 Feb 9. PMID: 31879979.

Smylie MG. Use of immuno-oncology in melanoma. Curr Oncol. 2020 Apr;27(Suppl 2):S51-S58. doi: 10.3747/co.27.5135. Epub 2020 Apr 1. PMID: 32368174; PMCID: PMC7194004.

. Jain V, Hwang WT, Venigalla S, Nead KT, Lukens JN, Mitchell TC, Shabason JE. Association of Age with Efficacy of Immunotherapy in Metastatic Melanoma. Oncologist. 2020 Feb;25(2):e381-e385. doi: 10.1634/theoncologist.2019-0377. Epub 2019 Oct 29. PMID: 32043765; PMCID: PMC7011618.

Ralli M, Botticelli A, Visconti IC, Angeletti D, Fiore M, Marchetti P, Lambiase A, de Vincentiis M, Greco A. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. J Immunol Res. 2020 Jun 28;2020:9235638. doi: 10.1155/2020/9235638. PMID: 32671117; PMCID: PMC7338969.

Lee EY, Kulkarni RP. Circulating biomarkers predictive of tumor response to cancer immunotherapy. Expert Rev Mol Diagn. 2019 Oct;19(10):895-904. doi: 10.1080/14737159.2019.1659728. Epub 2019 Sep 10. PMID: 31469965; PMCID: PMC6773262.

Wing A, Fajardo CA, Posey AD Jr, Shaw C, Da T, Young RM, Alemany R, June CH, Guedan S. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager. Cancer Immunol Res. 2018 May;6(5):605-616. doi: 10.1158/2326-6066.CIR-17-0314. Epub 2018 Mar 27. PMID: 29588319; PMCID: PMC6688490.

Winge-Main AK, Wälchli S, Inderberg EM. T cell receptor therapy against melanoma-Immunotherapy for the future? Scand J Immunol. 2020 Oct;92(4):e12927. doi: 10.1111/sji.12927. PMID: 32640053.

Li L, Liu S, Han D, Tang B, Ma J. Delivery and Biosafety of Oncolytic Virotherapy. Front Oncol. 2020 Apr 16;10:475. doi: 10.3389/fonc.2020.00475. PMID: 32373515; PMCID: PMC7176816.

Vesely MD, Chen L. Normalization Cancer Immunotherapy for Melanoma. J Invest Dermatol. 2020 Jun;140(6):1134-1142. doi: 10.1016/j.jid.2020.02.005. Epub 2020 Feb 22. PMID: 32092349; PMCID: PMC7247948.

Livingstone A, Agarwal A, Stockler MR, Menzies AM, Howard K, Morton RL. Preferences for Immunotherapy in Melanoma: A Systematic Review. Ann Surg Oncol. 2020 Feb;27(2):571-584. doi: 10.1245/s10434-019-07963-y. Epub 2019 Oct 29. PMID: 31664622.

McDermott D, Haanen J, Chen TT, Lorigan P, O'Day S; MDX010-20 investigators. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol. 2013 Oct;24(10):2694-2698. doi: 10.1093/annonc/mdt291. Epub 2013 Aug 13. PMID: 23942774.

Albittar AA, Alhalabi O, Glitza Oliva IC. Immunotherapy for Melanoma. Adv Exp Med Biol. 2020;1244:51-68. doi: 10.1007/978-3-030-41008-7_3. PMID: 32301010.

Chandran V, Gao K, Swarup V, Versano R, Dong H, Jordan MC, Geschwind DH. Inducible and reversible phenotypes in a novel mouse model of Friedreich's Ataxia. Elife. 2017 Dec 19;6:e30054. doi: 10.7554/eLife.30054. PMID: 29257745; PMCID: PMC5736353.

Wiesinger M, März J, Kummer M, Schuler G, Dörrie J, Schuler-Thurner B, Schaft N. Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance. Cancers (Basel). 2019 Aug 16;11(8):1198. doi: 10.3390/cancers11081198. PMID: 31426437; PMCID: PMC6721485

Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021 Mar;21(3):145-161. doi: 10.1038/s41568-020-00323-z. Epub 2021 Jan 22. PMID: 33483715; PMCID: PMC8353572.

Wang SY, Moore TV, Dalheim AV, Scurti GM, Nishimura MI. Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response. Sci Rep. 2021 Jun 25;11(1):13327. doi: 10.1038/s41598-021-92808-6. PMID: 34172810; PMCID: PMC8233420.

Yang T, Tang Y, Liu L, Lv X, Wang Q, Ke H, Deng Y, Yang H, Yang X, Liu G, Zhao Y, Chen H. Size-Dependent Ag2S Nanodots for Second Near-Infrared Fluorescence/Photoacoustics Imaging and Simultaneous Photothermal Therapy. ACS Nano. 2017 Feb 28;11(2):1848-1857. doi: 10.1021/acsnano.6b07866. Epub 2017 Jan 31. PMID: 28117993.

Liu Z, Cheng L, Zhang L, Yang Z, Liu Z, Fang J. Sub-100 nm hollow Au-Ag alloy urchin-shaped nanostructure with ultrahigh density of nanotips for photothermal cancer therapy. Biomaterials. 2014 Apr;35(13):4099-107. doi: 10.1016/j.biomaterials.2014.01.053. Epub 2014 Feb 8. PMID: 24518389.

Van de Broek B, Devoogdt N, D'Hollander A, Gijs HL, Jans K, Lagae L, Muyldermans S, Maes G, Borghs G. Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy. ACS Nano. 2011 Jun 28;5(6):4319-28. doi: 10.1021/nn1023363. Epub 2011 Jun 10. PMID: 21609027.

Nie C, Du P, Zhao H, Xie H, Li Y, Yao L, Shi Y, Hu L, Si S, Zhang M, Gu J, Luo L, Sun Z. Ag@TiO2 Nanoprisms with Highly Efficient Near-Infrared Photothermal Conversion for Melanoma Therapy. Chem Asian J. 2020 Jan 2;15(1):148-155. doi: 10.1002/asia.201901394. Epub 2019 Dec 5. PMID: 31802635.

Shahjamali MM, Bosman M, Cao S, Huang X, Cao X, Zhang H, Pramana SS, Xue C. Surfactant-free sub-2 nm ultrathin triangular gold nanoframes. Small. 2013 Sep 9;9(17):2880-6. doi: 10.1002/smll.201300200. Epub 2013 Feb 28. PMID: 23447112.

Jiang X, Zeng Q, Yu A. Thiol-frozen shape evolution of triangular silver nanoplates. Langmuir. 2007 Feb 13;23(4):2218-23. doi: 10.1021/la062797z. PMID: 17279717.

Li JF, Huang YF, Ding Y, Yang ZL, Li SB, Zhou XS, Fan FR, Zhang W, Zhou ZY, Wu DY, Ren B, Wang ZL, Tian ZQ. Shell-isolated nanoparticle-enhanced Raman spectroscopy. Nature. 2010 Mar 18;464(7287):392-5. doi: 10.1038/nature08907. PMID: 20237566.

Salehi F, Daneshvar F, Karimi M, Dehdari Vais R, Mosleh-Shirazi MA, Sattarahmady N. Enhanced melanoma cell-killing by combined phototherapy/radiotherapy using a mesoporous platinum nanostructure. Photodiagnosis Photodyn Ther. 2019 Dec;28:300-307. doi: 10.1016/j.pdpdt.2019.10.001. Epub 2019 Oct 10. PMID: 31606514.

Lifshits LM, Roque Iii JA, Konda P, Monro S, Cole HD, von Dohlen D, Kim S, Deep G, Thummel RP, Cameron CG, Gujar S, McFarland SA. Near-infrared absorbing Ru(ii) complexes act as immunoprotective photodynamic therapy (PDT) agents against aggressive melanoma. Chem Sci. 2020 Sep 9;11(43):11740-11762. doi: 10.1039/d0sc03875j. PMID: 33976756; PMCID: PMC8108386.

Lu YG, Wang YY, Yang YD, Zhang XC, Gao Y, Yang Y, Zhang JB, Li GL. Efficacy of topical ALA-PDT combined with excision in the treatment of skin malignant tumor. Photodiagnosis Photodyn Ther. 2014 Jun;11(2):122-6. doi: 10.1016/j.pdpdt.2014.02.006. Epub 2014 Feb 23. PMID: 24568889.

Yano T, Muto M, Minashi K, Iwasaki J, Kojima T, Fuse N, Doi T, Kaneko K, Ohtsu A. Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study. Int J Cancer. 2012 Sep 1;131(5):1228-34. doi: 10.1002/ijc.27320. Epub 2012 Mar 2. PMID: 22024814.

Lou PJ, Jäger HR, Jones L, Theodossy T, Bown SG, Hopper C. Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer. Br J Cancer. 2004 Aug 2;91(3):441-6. doi: 10.1038/sj.bjc.6601993. PMID: 15238981; PMCID: PMC2409848.

Isola V, Pece A, Pierro L. Photodynamic therapy with verteporfin of choroidal malignancy from breast cancer. Am J Ophthalmol. 2006 Nov;142(5):885-7. doi: 10.1016/j.ajo.2006.06.008. PMID: 17056382.

Simone CB 2nd, Cengel KA. Photodynamic therapy for lung cancer and malignant pleural mesothelioma. Semin Oncol. 2014 Dec;41(6):820-30. doi: 10.1053/j.seminoncol.2014.09.017. Epub 2014 Oct 7. PMID: 25499640; PMCID: PMC4272687.

Li XY, Tan LC, Dong LW, Zhang WQ, Shen XX, Lu X, Zheng H, Lu YG. Susceptibility and Resistance Mechanisms During Photodynamic Therapy of Melanoma. Front Oncol. 2020 May 12;10:597. doi: 10.3389/fonc.2020.00597. PMID: 32528867; PMCID: PMC7247862.

Huang YY, Vecchio D, Avci P, Yin R, Garcia-Diaz M, Hamblin MR. Melanoma resistance to photodynamic therapy: new insights. Biol Chem. 2013 Feb;394(2):239-50. doi: 10.1515/hsz-2012-0228. PMID: 23152406; PMCID: PMC3545031.

Pires L, Demidov V, Wilson BC, Salvio AG, Moriyama L, Bagnato VS, Vitkin IA, Kurachi C. Dual-Agent Photodynamic Therapy with Optical Clearing Eradicates Pigmented Melanoma in Preclinical Tumor Models. Cancers (Basel). 2020 Jul 18;12(7):1956. doi: 10.3390/cancers12071956. PMID: 32708501; PMCID: PMC7409296.

Downloads

  • PDF

Published

2021-09-05

How to Cite

1.
KLUZ, Natalia and KLAS, Jakub. Treatment of malignant melanoma - a review of the literature. Journal of Education, Health and Sport. Online. 5 September 2021. Vol. 11, no. 9, pp. 55-66. [Accessed 4 July 2025]. DOI 10.12775/JEHS.2021.11.09.008.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 11 No. 9 (2021)

Section

Review Articles

License

Copyright (c) 2021 © The Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 753
Number of citations: 0

Search

Search

Browse

  • Browse Author Index
  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

malignant melanoma, immunotherapy, photodynamic therapy
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop